Hilo, a medical technology company formerly known as Aktiia, has secured an oversubscribed $42 million Series B funding round, bringing its total financing to over $100 million. The investment was co-led by Earlybird Health and Wellington Partners, with participation from new investors Kfund and naturalX Health Ventures, as well as existing investors redalpine, Khosla Ventures, Molten Ventures, Translink Capital, and Verve Ventures.
Cuffless Blood Pressure Monitoring Advancements
The funding will be used to accelerate Hilo’s cuffless blood pressure monitoring (CBPM) technology, expand into new markets, and develop its blood pressure intelligence platform for enterprise use cases. Hilo’s technology uses AI algorithms and extensive datasets to deliver clinically validated blood pressure readings through a mobile phone camera.
Recent Regulatory Progress
The company has recently secured CE mark approval for its mobile phone camera blood pressure monitoring technology and has also received approval in Canada, Australia, and Saudi Arabia. Hilo has completed a pivotal clinical trial in preparation for an FDA submission in the U.S. and has already sold over 120,000 devices, establishing itself as a leader in the emerging CBPM category.
Transforming Blood Pressure Management
“This funding round is a testament to the confidence our investors have in Hilo’s groundbreaking technology and our mission to manage the world’s blood pressure via more frequent, convenient, and accurate measurements,” said Raghav “Rags” Gupta, Hilo CEO. The company aims to make cuffless, clinically validated blood pressure monitoring universally accessible and effortless, reflecting its global ambition with the rebrand from Aktiia to Hilo.
Future Plans
The rebranding represents a commitment to empowering users worldwide with smarter health optimization tools. With billions of people suffering from hypertension, of which only 20% are in control of their blood pressure, Hilo believes the need for innovative, accessible blood pressure monitoring solutions has never been greater. The company plans to continue delivering its trusted blood pressure monitoring technology while expanding its global presence.
